he London-based biopharmaceutical company exceeded consensus analyst expectations of 102.4 million dollars in sales for the last quarter of 2019, reporting approximately 108 million to investors, and 309 million dollars over the whole year. GW’s anti-seizure CBD epilepsy medication Epidiolex was responsible for the majority of those sales, earning 104 out of the 108 million. Recent marketing authorization from the EU and eligibility for coverage by the UK’s National Health Service may have contributed to the increase although GW hasn’t specified what percentage of Epidiolex sales were in Europe. GW also owns the drug Sativex, for treatment of multiple sclerosis, which is approved in Europe but not the US. The unaudited figures were announced ahead of meetings to entice potential investors. GW’s goals for 2020 include obtaining approval for Epidiolex in the treatment of Tuberous Sclerosis Syndrome and research it’s use for Rett Syndrome to expand their patient base, as well as developing new formulations to treat autism and schizophrenia, which will, no doubt, require significant funding. Directed by: Micah Tatum @arbitrageent
News Anchor: Jacqui Verdura
Distributed by: Cannabis Broadcast Station/ Infinity Broadcast Network Sponsored by: Infinity Inc.
Follow Us on IG,Twitter, Facebook: @cannabisbroadcaststaion @infinitybrandsinc @cannabissnacks
IG:
IG:
TW:
TW:
0 Comments